NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

On November 17, 2025, NewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board, not as Chief Marketing Officer (CMO), but as a distinguished clinical research leader and ALS expert1 5 6.

Prof. Shefner is Chief Medical Officer for Clinical Research at the Barrow Neurological Institute and has co-founded the Northeast ALS Clinical Trials Consortium (NEALS), with over 200 peer-reviewed ALS-related publications1 3 5.

His role will be to provide strategic guidance for NewcelX’s ALS programs, especially the clinical development of AstroRx®, and to help integrate expertise in neuromuscular and neurodegenerative diseases into the company's cell therapy platform1 3 5 9.

NewcelX leadership highlighted Shefner’s influence in ALS research and his experience in innovative trial methodologies—including biomarker-driven and adaptive trial designs—as critical to advancing their therapeutic pipeline3 5.

The appointment aligns NewcelX with industry trends emphasizing the importance of high-caliber scientific advisory leadership in biotech innovation for neurodegenerative diseases, specifically ALS3.

There is no public news or official filing indicating Jeremy Shefner was appointed as Chief Marketing Officer (CMO); all recent reports reference his appointment to the Scientific Advisory Board1 2 5.